Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 3/20 | 0.63 |
| ▸ | CCR5 | P51681 | 3/20 | 0.63 |
| ▸ | CCR8 | P51685 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | METAP1 | P53582 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | ALPL | P05186 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545764 | 1.00 | CCR1 (0.63) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL30423972 | 0.92 | TDP1 (0.68) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL1442585 | 0.92 | TDP1 (0.68) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL25004067 | 0.87 | CCR1 (0.58) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL9487125 | 0.87 | KDM4E (0.57) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL7152644 | 0.86 | KDM4E (0.77) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL2369433 | 0.85 | CCR1 (0.63) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL1444155 | 0.84 | L3MBTL1 (0.58) | CCR1CCR5CCR8KDM4ETDP1 | |
| SCHEMBL5480168 | 0.84 | GRM5 (0.61) | KDM4ETDP1METAP1LMNAMAPK1 | |
| SCHEMBL10157013 | 0.84 | KDM4E (0.57) | CCR1CCR5CCR8KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0431421-A2 | Heteroarylsubstituted pyridinylpyrimidin derivatives | BAYER AG (DE) | 1991-06-12 | — | — | EP | claimed |
| WO-2018033610-A1 | LIGANDS, ELECTROCHROMIC METALLO-POLYMERS OBTAINED THEREWITH AND THEIR USE | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018033610-A1 | LIGANDS, ELECTROCHROMIC METALLO-POLYMERS OBTAINED THEREWITH AND THEIR USE | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2018-02-22 | — | — | WO | disclosed |
| EP-3284801-A1 | LIGANDS, ELECTROCHROMIC METALLO-POLYMERS OBTAINED THEREWITH AND THEIR USE | Julius-Maximilians-Universität Würzburg (DE) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284801-A1 | LIGANDS, ELECTROCHROMIC METALLO-POLYMERS OBTAINED THEREWITH AND THEIR USE | Julius-Maximilians-Universität Würzburg (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-7560464-B2 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7226927-B2 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-12-01 | — | — | US | disclosed |
| EP-1351691-A4 | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA INC (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2004-05-20 | — | — | US | disclosed |
| US-5120843-A | Nervous system disorders | UPJOHN (US) | 1992-06-09 | — | — | US | disclosed |
| EP-0487510-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5099019-A | Central nervous system steroid derivative drugs | UPJOHN COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0431421-A2 | Heteroarylsubstituted pyridinylpyrimidin derivatives | BAYER AG (DE) | 1991-06-12 | — | — | EP | disclosed |
| US-4996318-A | Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke | THE UPJOHN COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0354920-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1990-02-21 | — | — | EP | disclosed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | disclosed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267089-A1 | Polycyclic pyrimidines as potassium ion channel modulators | KCNJ2, KCNJ1, KCNJ11 | CCR1 4553/4885CCR5 3263/4885CCR8 4393/4885 |
| US-20040097503-A1 | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof | API5, CASP2, APAF1 | CCR1 1240/4885CCR5 2554/4885CCR8 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.